Kornimate/medical-research-clean huggingface dataset:
comparison of oral ferrous sulfate to intravenous ferumoxytol in antepartum iron deficiency anemia

Conditions: Pregnancy Related; Anemia, Iron Deficiency

Summary: evaluate the extent to which treatment of iron deficiency anemia beyond 24-34 weeks' gestation of pregnancy with intravenous iron increases hemoglobin compared to oral iron. the investigators will test the hypothesis that pregnant women who are anemic in the second and third trimester are more likely to significantly increase their hemoglobin with intravenous iron as opposed to the usual standard of care, oral iron.


Eligibility criteria:
inclusion criteria: 1. pregnant women 18 years old and above 2. hemoglobin \< 11 g/dl, serum ferritin \< 30 ug/dl and or transferrin saturation (tsat) \< 20% 3. between 24-34 weeks' pregnancy 4. singleton pregnancy 5. receiving prenatal care at stanford/lpch ob clinic and planning to deliver at lpch 6. hemodynamically stable exclusion criteria: 1. patients unable to give informed consent 2. known allergy/hypersensitivity to iv iron 3. inflammatory bowel disease or history of gastric bypass surgery 4. dialysis-dependent chronic kidney disease/ esrd 5. known hemoglobinopathies such as sickle cell disease, beta-thalassemia, alpha thalassemia 6. folate/vitamin b12 deficiency 7. known malignancy 8. medication allergy to tylenol (acetaminophen) 9. hemoglobin above 12 or less than 7 g/dl 10. patients with complex past medical histories which may include history of multiple medication allergies (greater than 2 allergies), connective tissue disorder, etc. 11. diagnosis of placenta previa
walking or high intensity exercise for anxiety

Conditions: Generalized Anxiety Disorder; Panic Disorder; Social Anxiety

Summary: after an initial phone screen process, approximately 50 participants will be enrolled and evaluated/screened in person after consenting to achieve 30 eligible participants with a principal diagnosis of gad, panic disorder, or social anxiety disorder and high anxiety sensitivity (anxiety sensitivity index score =20). participants will be given a choice of either high intensity interval training (hiit) or walking interventions, which will be completed over the course of 8 weeks. the goal of the study is to 1) obtain pilot data comparing the efficacy of hiit vs. walking for effects on psychiatric, functioning and immune outcomes, 2) to identify adherence levels given the choice of exercise intensity, and 3) to identify proportion of individuals opting for each intervention. results from this pilot study will be used to inform future grant applications including a k award.


Eligibility criteria:
inclusion criteria: * anxiety sensitivity index score of ≥20 (i.e., high anxiety sensitivity) * primary psychiatric diagnosis of generalized anxiety disorder (gad), social anxiety disorder, or panic disorder * currently sedentary (≤60 minutes of moderate intensity exercise per week for the past 3 months) * able and willing to provide informed consent exclusion criteria: * lifetime history of bipolar i or ii or any psychotic disorder * meets criteria for bulimia or anorexia in the past 6 months * meets criteria for substance use disorder in the past 3 months * high current suicide risk as indicated by a score of ≥4 on the c-ssrs * risk for exercise according to physical activity readiness questionnaire with excluded medical conditions including heart conditions, lung disease, bone/joint problems, or seizures * women who are currently pregnant or plan to become pregnant during the duration of the study * participation in concurrent evidence-based therapy (e.g., cognitive behavioral therapy) targeting anxiety or depression (supportive therapy and couples therapy are allowed) * participants on psychiatric medication must be on a stable dose for ≥8 weeks prior to participation * current substance abuse or positive urine toxic screen (recreational use of marijuana is permitted based on clinical assessment on the mini that it does not meet criteria for cannabis use disorder)
endoscopic full thickness resection in the lower gi tract with the "full thickness resection device"

Conditions: Colorectal Adenomas; Submucosal Tumors

Summary: observational prospective multicenter study to investigate efficacy and safety of endoscopic full thickness resection in the lower gi tract using a novel over-the-scope full thickness resection device.

the ftrd ("full thickness resection device", ovesco endoscopy, tübingen, germany) is an over the scope device consisting of a transparent cap with a preloaded monofilament snare and and a 14 mm modified over-the-scope clip. the device is ce marked for full thickness resection in the lower gi tract. the study was designed to investigate efficacy and safety of this device for full thickness resection of colorectal lesions.

Eligibility criteria:
inclusion criteria: * age \> 18 y * adenoma with negtive lifting sign * adenoma involving or next to a diverticulum * adenoma involving or next to the appendical orifice * t1 carcinoma with indication for endoscopic (re-)resection * subepithelial colorectal tumor with indication for resection exclusion criteria: * lesions \>3 cm * t1 carcinomas with known high-risk features (submucosal infiltration\>1000 um, invasion of lymphatic vessels, poor differentiation (g3)) * lesions in the upper gi tract * patients with colorectal stenosis * patinets not able to undergo informed consent * pregnancy * patients with urgent indication for dual thrombocyte aggregation inhibition

Keywords: endoscopic full thickness resection eftr ftrd otsc
observational trial of hepatitis c virus infected patients on calcineurin inhibitors

Conditions: Hepatitis C Virus

Summary: hepatitis c virus is constantly evolving genetically, particularly in response to the immune system. this is an observational study to examine if immunosuppressants particularly calcineurin inhibitors taken by transplant patients in order to avoid organ rejection causes predictable changes in the genetics of this virus that might be important in order to treat it effectively.


Eligibility criteria:
inclusion criteria: * hcv infected on immunosuppression
cell culture of glioma specimens for in vitro preclinical studies

Conditions: Brain Tumor

Summary: the purpose of this study is to culture primary human brain tumor cells with the specific aims of: 1. develop primary cultures from human brain tumor surgical specimens 2. determine the genetic and molecular fingerprints of brain tumors that may have prognostic significance 3. delineate the mechanisms underlying oncogenesis of brain tumors. 4. perform in vitro assays with brain tumor derived primary cultures to assess the efficacy of novel therapeutic agents.


Eligibility criteria:
inclusion criteria: * patients 18 years of age or older undergoing surgical resection for glioma exclusion criteria: * under 18 years of age
remune + amplivax ir103 hiv/aids phase iii safety & efficacy study

Conditions: HIV

Summary: the primary objective is to compare \& evaluate between the treatment groups the changes in decline/reduction of hiv viral load changes in the remune + amplivax group vs the amplivax placebo groups. additional objectives include changes in wbc white blood cell counts \& cd4+ \& cd8+ t cell counts along with increased hiv immunity.

this is a 500 subject multi center double-blind randomized, safety \& efficacy, hiv/aids phase iii study, to primarily to evaluate the safety and efficacy of hiv-1 immunogen \& amplivax compared to placebo group amplivax in viral load, and secondarily to examine changes in cd4+ \& cd8+ t cell counts, determine remune vaccines effect of multiple inoculations of hiv-1 immunogen + amplivax on viral replication in adults with hiv-1 infection \& to examine immunogenicity of remune + amplivax in a multi-center, randomized , double-blind, placebo-controlled, two arm parallel design study of remune + amplivax.

Eligibility criteria:
inclusion criteria: * are hiv-positive and started anti-hiv drugs soon after tests showed the presence of hiv. * are at least 16 years old (consent of parent or guardian required if under 18 years). exclusion criteria: * healthy subjects * currently abuse alcohol or drugs.

Keywords: hiv
move your spondyl " better live its rheumatism with the physical activity "

Conditions: Spondyloarthritis

Summary: by this project, the investigators are going to try to demonstrate that to use objects connected to make a physical activity can have an impact on the clinical activity of the disease by bringing the subjects which present a spondyloarthritis to make a physical activity. the investigators shall show furthermore, than the use of connected objects also has better chances to glue the patients presenting a spondyloarthritis to a practice of regular physical activity that a simple recommendation.

this project is aimed at subjects with axial spondyloarthritis and / or peripheral of the alpes maritimes and more specifically of the city of nice and its surroundings. the subjects will be recruited by the hospital doctors (consultations, hospitalization). patients will benefit from an inclusion visit in order to explain the protocol, sign the study consent and eliminate a possible contraindication to physical activity. knowing that this is a physical activity adapted to the health of people and their physical abilities.

Eligibility criteria:
inclusion criteria: * presenting a spondyloarthritis according to the criteria of the asas (l'assessment of spondyloarthritis international society) * benefiting from a stable treatment by biotherapies for at least 3 months exclusion criteria: * patient presenting a cardiac pathology should be decompensating * patients having a contraindication in the physical activity * lung affection making impossible the effort * patient already realizing a physical activity supervised in club or with sports coach

Keywords: activity connected object
evaluation of alirocumab versus ezetimibe on top of statin in asia in high cardiovascular risk patients with hypercholesterolemia

Conditions: Hypercholesterolemia

Summary: primary objective: to demonstrate the reduction of low-density lipoprotein cholesterol (ldl-c) by alirocumab as add-on therapy to stable maximally tolerated daily statin therapy in comparison to ezetimibe 10 mg daily after 24 weeks of treatment in asia in participants with hypercholesterolemia at high cardiovascular (cv) risk. secondary objectives: * to evaluate the effect of alirocumab 75 mg in comparison with ezetimibe 10 mg on ldl-c after 12 weeks of treatment. * to evaluate the effect of alirocumab on other lipid parameters: e.g., apolipoprotein b (apo b), non-high density lipoprotein cholesterol (non-hdl-c), total cholesterol (tc), lipoprotein a (lp\[a\]), hdl-c, triglycerides (tg), apolipoprotein a-1 (apo a-1). * to evaluate the safety and tolerability of alirocumab. * to evaluate the development of anti-alirocumab antibodies. * to evaluate the pharmacokinetics (pk) of alirocumab.

the maximum study duration was 35 weeks per participant, which included a screening period of up to 3 weeks, a 24-week randomized treatment period, and an 8-week post-treatment follow-up period.

Eligibility criteria:
inclusion criteria: participants with hypercholesterolemia and established coronary heart disease (chd) or chd risk equivalents who are not adequately controlled with a maximally tolerated daily dose of statin at a stable dose for at least 4 weeks prior to the screening visit (week -3). exclusion criteria: * participants without established chd or chd risk equivalents. * ldl-c \<70 mg/dl (\<1.81 mmol/l) at the screening visit (week -3) in participants with history of documented cv disease. * ldl-c \<100 mg/dl (\<2.59 mmol/l) at the screening visit (week -3) in participants without history of documented cv disease. * change in statin dose or dose regimen from screening to randomization. * currently taking a statin other than atorvastatin, rosuvastatin, or simvastatin. * atorvastatin, rosuvastatin, or simvastatin was not taken daily or not taken at a registered dose. * daily doses above atorvastatin 80 mg, rosuvastatin 40 mg, or simvastatin 40 mg. * use of cholesterol absorption inhibitor (ie, ezetimibe), omega-3 fatty acid (at doses ≥1000 mg daily), nicotinic acid, fibrates, bile acid-binding sequestrant, or red yeast rice products in the past 4 weeks prior to screening visit (week -3). * fasting serum triglycerides \>400 mg/dl (\>4.52 mmol/l) at the screening period. the above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
motor learning-based clinical pilates rehabilitation protocol for patients with parkinson's disease

Conditions: Parkinson Disease

Summary: individuals with parkinson's disease demonstrate impaired motor learning, including a slower acquisition rate and poor retention, which may result from deficits in cognitive function, especially executive function. considering the reduced motor learning ability in this patient group, exercises should be designed with a focus on strengthening sensory inputs and basic functional training. therefore, the investigators established this program according to previous experience published study \[nct04063605\]. therefore, the feasibility of this rehabilitation protocol, which combines motor learning and clinical pilates principles and is adapted to the needs of individuals with parkinson's disease, will be examined.

the patients with parkinson's disease will be randomly assigned into two groups: motor learning based clinical pilates (mlcp) group and conventional physiotherapy (cp) group. both groups will be treated for 12 weeks. the evaluation of the patients will be done before the beginning of exercise program, midterm evaluation in the 6th week and will be repeated at the end. also there will be followed up evaluation with the same assessments at the 3rd month. physical function/motor function of patients will be evaluated with the unified parkinson's disease rating scale (updrs) iii subscale, dynamic balance with functional reach test (frt), postural control and dynamic balance will also be evaluated with berg balance scale and functional mobility by timed up and go test. gait, balance and functional domains of the patients will be evaluated with gait and balance scale (gabs), nelson foot reaction test will be used for the reaction time.

Eligibility criteria:
inclusion criteria: * having modified hoehn \& yahr scale grade 2-3 symptoms * be over 45 years old * having a score of 24 or 24\< on the mini mental test * to be able to read and write in turkish * having at least 2 years parkinson's disease exclusion criteria: * serious mental and psychological disorder * significant musculoskeletal disorders * lower extremity deformation * having another neurological disease * drug or dose change during treatment

Keywords: parkinson disease exercise
depot-medroxyprogesterone acetate (dmpa) contraceptive method and metabolism

Conditions: Insulin Resistance; Cardiovascular Disease; Bone Loss; Eating Disorders; Thrombosis

Summary: objective: the purpose of this study is to determine the etiology of the weight increase in depot-medroxyprogesterone acetate (dmpa) users. method: prospective study with 100 women, aged 18-40 years old and bmi \< 30kg/m², paired with users of a non hormonal method follow for two years. will be included only women who never used dmpa. there will be evaluated habit, blood pressure, anthropometric measure, distribution of corporal fat, lipids profile and glycemia parameters every six months. thirty women and their control group will performed a euglycemic-hyperinsulinemic clamp to evaluate the resistance of insulin, adiponectin,neuropeptide y, apolipoprotein a/b and arterial evaluation with ultrasound, intimal and media measure. anova analysis for repeated samples. the metabolic alterations should elucidate the etiology, and the beginning of the sub clinical cardiovascular disease should be shown/discarded with the arterial evaluation.


Eligibility criteria:
inclusion criteria: * 18-40 years * new users of dmpa * bmi\<30kg/m² exclusion criteria: * diabetes mellitus and 2 present or fasting glucose\> 100mg/dl and / or blood glucose\> 140mg/dl after ingestion of 75mg of oral glucose * first-degree relatives with diabetes mellitus * period of lactation * hypertension, with or without treatment * hyper and hypothyroidism * chronic renal failure * transplant of any organ * women using drugs that may be related to weight gain and / or development of insulin resistance and chronic use of corticosteroids, antipsychotics, statins, and thiazide, * hirsutism and/or hyperandrogenism * polycystic ovary syndrome (pcos) * women with acanthosis nigricans * women who have used depoprovera at some point in their reproductive lives, * women who have performed bariatric surgery

Keywords: dmpa insulin resistance cardiovascular disease bmi weight gain thrombosis
hifem for arms, lower limbs, and oblique muscles

Conditions: Muscle Tone Increased

Summary: evaluation of hifem treatments for strengthening and toning of arms, lower limbs and oblique muscles.

this study will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of arm, lower limb and oblique muscles. the study is a prospective multi-center open-label four-arm study.

Eligibility criteria:
inclusion criteria: * voluntarily signed informed consent form * bmi ≤ 30 kg/m2 * women of child-bearing potential are required to use birth control measures during the whole duration of the study * subjects willing and able to abstain from partaking in any treatments other than the study procedure to promote body contouring during study participation * subjects willing and able to maintain her regular (pre-procedure) diet and exercise regimen without effecting significant change in either direction during study participation exclusion criteria: * cardiac pacemakers * implanted defibrillators, implanted neurostimulators * electronic implants * pulmonary insufficiency * metal implants * drug pumps * application in the head area * application in the heart area * malignant tumor * injured or otherwise impaired muscles * fever * pregnancy * sensitivity or allergy to latex * breastfeeding * following recent surgical procedures when muscle contraction may disrupt the healing process * application over areas of the skin which lack normal sensation * scars, open lesions and wounds at the treatment area * unrepaired abdominal hernia * patients after cesarean section delivery

Keywords: muscle strengthening muscle tone
individualized treatment of pediatric r/r aml based on transcriptomic profile and in vitro drug sensitivity test

Conditions: Acute Myeloid Leukemia in Children

Summary: acute myeloid leukemia (aml) accounts for about 15% to 20% of childhood leukemia, but the death rate accounts for about 50%. about 20-30% of children with aml did not achieve complete response (cr) after 2 induction treatments, and about 30% of children with cr had relapse within 3 years (including recurrence after hematopoietic stem cell transplantation).relapsed/refractory (r/r) aml is a major cause of treatment failure and refractory survival. reinduction chemotherapy for r/r-aml to obtain cr again, followed by hematopoietic stem cell transplantation, is the current treatment. at present, there is no recognized reinduction protocol, and the reinduction remission rate of r/r-aml varies greatly among different treatment regimens, ranging from 23 to 81%. current guidelines recommend a new combination chemotherapy regimen consisting of new drugs without cross-resistance. this method selects sensitive chemotherapeutic drugs, and then forms a new combination chemotherapy regimen according to the characteristics of drugs, which is the choice of r/r-aml reinduction therapy.this study intends to conduct a clinical study on the individualized treatment of r/r aml patients through in vitro drug sensitivity test combined with patient transcriptomic characteristics.


Eligibility criteria:
inclusion criteria: - (1) refractory recurrent acute myeloid leukemia (aml), and after second-line reinduction therapy, such as c+hag did not reach complete cr.criteria for complete response, refractory, and recurrence are as follows. (2) \<18 years old; (3) the child had good organ function, could tolerate chemotherapy, and had a physical strength score of 0-3 (who standard); (4) understand the research procedures and voluntarily sign written informed consent. exclusion criteria: - (1) acute promyelocytic leukemia, chronic myelogenous leukemia, acute mixed cell leukemia or known central nervous system leukemia; (2) aml associated with congenital syndromes such as down syndrome, fanconi anemia, bloom syndrome, cole's syndrome, or congenital aplastic anemia; (3) secondary to immunodeficiency or positive for human immunodeficiency virus (hiv); (4) cardiac and renal function were obviously abnormal, and left ventricular ejection fraction was \<50%. (5) there is active systemic infection; (6) any medical history or concomitant condition that the investigator believes would impair the subject's safe completion of the study; (7) the investigator considers that the subject is medically unfit to receive the investigational drug or is unfit for any other reason; (8) a known or suspected allergy to the subject drug or to any drug administered in connection with this test;

Keywords: acute myeloid leukemia relapsed/refractory transcriptomic sequencing drug sensitivity test